Common pathway signature in lung and liver fibrosis

Eugene Makarev, Evgeny Izumchenko, Fumiaki Aihara, Piotr T. Wysocki, Qingsong Zhu, Anton Buzdin, David Sidransky, Alex Zhavoronkov, Anthony Atala

Research output: Contribution to journalArticle

Abstract

Fibrosis, a progressive accumulation of extracellular matrix components, encompasses a wide spectrum of distinct organs, and accounts for an increasing burden of morbidity and mortality worldwide. Despite the tremendous clinical impact, the mechanisms governing the fibrotic process are not yet understood, and to date, no clinically reliable therapies for fibrosis have been discovered. Here we applied Regeneration Intelligence, a new bioinformatics software suite for qualitative analysis of intracellular signaling pathway activation using transcriptomic data, to assess a network of molecular signaling in lung and liver fibrosis. In both tissues, our analysis detected major conserved signaling pathways strongly associated with fibrosis, suggesting that some of the pathways identified by our algorithm but not yet wet-lab validated as fibrogenesis related, may be attractive targets for future research. While the majority of significantly disrupted pathways were specific to histologically distinct organs, several pathways have been concurrently activated or downregulated among the hepatic and pulmonary fibrosis samples, providing new evidence of evolutionary conserved pathways that may be relevant as possible therapeutic targets. While future confirmatory studies are warranted to validate these observations, our platform proposes a promising new approach for detecting fibrosis-promoting pathways and tailoring the right therapy to prevent fibrogenesis.

Original languageEnglish (US)
Pages (from-to)1-7
Number of pages7
JournalCell Cycle
DOIs
StateAccepted/In press - Jun 8 2016

Fingerprint

Liver Cirrhosis
Fibrosis
Lung
Pulmonary Fibrosis
Computational Biology
Intelligence
Extracellular Matrix
Regeneration
Therapeutics
Down-Regulation
Software
Morbidity
Mortality
Liver

Keywords

  • algorithm
  • bioinformatics
  • IPF
  • liver fibrosis
  • PAS
  • pathway activation
  • signaling pathway signature

ASJC Scopus subject areas

  • Cell Biology
  • Molecular Biology
  • Developmental Biology

Cite this

Makarev, E., Izumchenko, E., Aihara, F., Wysocki, P. T., Zhu, Q., Buzdin, A., ... Atala, A. (Accepted/In press). Common pathway signature in lung and liver fibrosis. Cell Cycle, 1-7. https://doi.org/10.1080/15384101.2016.1152435

Common pathway signature in lung and liver fibrosis. / Makarev, Eugene; Izumchenko, Evgeny; Aihara, Fumiaki; Wysocki, Piotr T.; Zhu, Qingsong; Buzdin, Anton; Sidransky, David; Zhavoronkov, Alex; Atala, Anthony.

In: Cell Cycle, 08.06.2016, p. 1-7.

Research output: Contribution to journalArticle

Makarev, E, Izumchenko, E, Aihara, F, Wysocki, PT, Zhu, Q, Buzdin, A, Sidransky, D, Zhavoronkov, A & Atala, A 2016, 'Common pathway signature in lung and liver fibrosis', Cell Cycle, pp. 1-7. https://doi.org/10.1080/15384101.2016.1152435
Makarev E, Izumchenko E, Aihara F, Wysocki PT, Zhu Q, Buzdin A et al. Common pathway signature in lung and liver fibrosis. Cell Cycle. 2016 Jun 8;1-7. https://doi.org/10.1080/15384101.2016.1152435
Makarev, Eugene ; Izumchenko, Evgeny ; Aihara, Fumiaki ; Wysocki, Piotr T. ; Zhu, Qingsong ; Buzdin, Anton ; Sidransky, David ; Zhavoronkov, Alex ; Atala, Anthony. / Common pathway signature in lung and liver fibrosis. In: Cell Cycle. 2016 ; pp. 1-7.
@article{39019f27a791401abe6830c264da0dff,
title = "Common pathway signature in lung and liver fibrosis",
abstract = "Fibrosis, a progressive accumulation of extracellular matrix components, encompasses a wide spectrum of distinct organs, and accounts for an increasing burden of morbidity and mortality worldwide. Despite the tremendous clinical impact, the mechanisms governing the fibrotic process are not yet understood, and to date, no clinically reliable therapies for fibrosis have been discovered. Here we applied Regeneration Intelligence, a new bioinformatics software suite for qualitative analysis of intracellular signaling pathway activation using transcriptomic data, to assess a network of molecular signaling in lung and liver fibrosis. In both tissues, our analysis detected major conserved signaling pathways strongly associated with fibrosis, suggesting that some of the pathways identified by our algorithm but not yet wet-lab validated as fibrogenesis related, may be attractive targets for future research. While the majority of significantly disrupted pathways were specific to histologically distinct organs, several pathways have been concurrently activated or downregulated among the hepatic and pulmonary fibrosis samples, providing new evidence of evolutionary conserved pathways that may be relevant as possible therapeutic targets. While future confirmatory studies are warranted to validate these observations, our platform proposes a promising new approach for detecting fibrosis-promoting pathways and tailoring the right therapy to prevent fibrogenesis.",
keywords = "algorithm, bioinformatics, IPF, liver fibrosis, PAS, pathway activation, signaling pathway signature",
author = "Eugene Makarev and Evgeny Izumchenko and Fumiaki Aihara and Wysocki, {Piotr T.} and Qingsong Zhu and Anton Buzdin and David Sidransky and Alex Zhavoronkov and Anthony Atala",
year = "2016",
month = "6",
day = "8",
doi = "10.1080/15384101.2016.1152435",
language = "English (US)",
pages = "1--7",
journal = "Cell Cycle",
issn = "1538-4101",
publisher = "Landes Bioscience",

}

TY - JOUR

T1 - Common pathway signature in lung and liver fibrosis

AU - Makarev, Eugene

AU - Izumchenko, Evgeny

AU - Aihara, Fumiaki

AU - Wysocki, Piotr T.

AU - Zhu, Qingsong

AU - Buzdin, Anton

AU - Sidransky, David

AU - Zhavoronkov, Alex

AU - Atala, Anthony

PY - 2016/6/8

Y1 - 2016/6/8

N2 - Fibrosis, a progressive accumulation of extracellular matrix components, encompasses a wide spectrum of distinct organs, and accounts for an increasing burden of morbidity and mortality worldwide. Despite the tremendous clinical impact, the mechanisms governing the fibrotic process are not yet understood, and to date, no clinically reliable therapies for fibrosis have been discovered. Here we applied Regeneration Intelligence, a new bioinformatics software suite for qualitative analysis of intracellular signaling pathway activation using transcriptomic data, to assess a network of molecular signaling in lung and liver fibrosis. In both tissues, our analysis detected major conserved signaling pathways strongly associated with fibrosis, suggesting that some of the pathways identified by our algorithm but not yet wet-lab validated as fibrogenesis related, may be attractive targets for future research. While the majority of significantly disrupted pathways were specific to histologically distinct organs, several pathways have been concurrently activated or downregulated among the hepatic and pulmonary fibrosis samples, providing new evidence of evolutionary conserved pathways that may be relevant as possible therapeutic targets. While future confirmatory studies are warranted to validate these observations, our platform proposes a promising new approach for detecting fibrosis-promoting pathways and tailoring the right therapy to prevent fibrogenesis.

AB - Fibrosis, a progressive accumulation of extracellular matrix components, encompasses a wide spectrum of distinct organs, and accounts for an increasing burden of morbidity and mortality worldwide. Despite the tremendous clinical impact, the mechanisms governing the fibrotic process are not yet understood, and to date, no clinically reliable therapies for fibrosis have been discovered. Here we applied Regeneration Intelligence, a new bioinformatics software suite for qualitative analysis of intracellular signaling pathway activation using transcriptomic data, to assess a network of molecular signaling in lung and liver fibrosis. In both tissues, our analysis detected major conserved signaling pathways strongly associated with fibrosis, suggesting that some of the pathways identified by our algorithm but not yet wet-lab validated as fibrogenesis related, may be attractive targets for future research. While the majority of significantly disrupted pathways were specific to histologically distinct organs, several pathways have been concurrently activated or downregulated among the hepatic and pulmonary fibrosis samples, providing new evidence of evolutionary conserved pathways that may be relevant as possible therapeutic targets. While future confirmatory studies are warranted to validate these observations, our platform proposes a promising new approach for detecting fibrosis-promoting pathways and tailoring the right therapy to prevent fibrogenesis.

KW - algorithm

KW - bioinformatics

KW - IPF

KW - liver fibrosis

KW - PAS

KW - pathway activation

KW - signaling pathway signature

UR - http://www.scopus.com/inward/record.url?scp=84974834743&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84974834743&partnerID=8YFLogxK

U2 - 10.1080/15384101.2016.1152435

DO - 10.1080/15384101.2016.1152435

M3 - Article

C2 - 27267766

AN - SCOPUS:84974834743

SP - 1

EP - 7

JO - Cell Cycle

JF - Cell Cycle

SN - 1538-4101

ER -